NASDAQ:GLSI Greenwich LifeSciences (GLSI) Stock Price, News & Analysis $14.06 -0.33 (-2.29%) (As of 11/11/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends About Greenwich LifeSciences Stock (NASDAQ:GLSI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Greenwich LifeSciences alerts:Sign Up Key Stats Today's Range$13.67▼$14.6750-Day Range$12.90▼$15.2952-Week Range$8.00▼$21.44Volume17,172 shsAverage Volume40,115 shsMarket Capitalization$184.89 millionP/E RatioN/ADividend YieldN/APrice Target$38.00Consensus RatingBuy Company OverviewGreenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.Read More… This company will win the AI race (Ad)Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. Greenwich LifeSciences Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks31st Percentile Overall ScoreGLSI MarketRank™: Greenwich LifeSciences scored higher than 31% of companies evaluated by MarketBeat, and ranked 806th out of 977 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingGreenwich LifeSciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageGreenwich LifeSciences has only been the subject of 1 research reports in the past 90 days.Read more about Greenwich LifeSciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Greenwich LifeSciences are expected to decrease in the coming year, from ($0.81) to ($0.82) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Greenwich LifeSciences is -17.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Greenwich LifeSciences is -17.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGreenwich LifeSciences has a P/B Ratio of 27.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Greenwich LifeSciences' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.47% of the float of Greenwich LifeSciences has been sold short.Short Interest Ratio / Days to CoverGreenwich LifeSciences has a short interest ratio ("days to cover") of 16.3, which indicates bearish sentiment.Change versus previous monthShort interest in Greenwich LifeSciences has recently increased by 1.11%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGreenwich LifeSciences does not currently pay a dividend.Dividend GrowthGreenwich LifeSciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.47% of the float of Greenwich LifeSciences has been sold short.Short Interest Ratio / Days to CoverGreenwich LifeSciences has a short interest ratio ("days to cover") of 16.3, which indicates bearish sentiment.Change versus previous monthShort interest in Greenwich LifeSciences has recently increased by 1.11%, indicating that investor sentiment is decreasing. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Greenwich LifeSciences this week, compared to 1 article on an average week.Search Interest2 people have searched for GLSI on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Greenwich LifeSciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $33,025.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders52.86% of the stock of Greenwich LifeSciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 4.16% of the stock of Greenwich LifeSciences is held by institutions.Read more about Greenwich LifeSciences' insider trading history. Receive GLSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Greenwich LifeSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address GLSI Stock News HeadlinesGreenwich LifeSciences (NASDAQ:GLSI) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comGreenwich LifeSciences, Inc. (NASDAQ:GLSI) insiders seem bullish, own 55% and have been buying more recentlySeptember 12, 2024 | finance.yahoo.comElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.November 12, 2024 | Porter & Company (Ad)Insider Stock Buying Reaches US$3.36m On Greenwich LifeSciencesAugust 17, 2024 | uk.finance.yahoo.comGreenwich Lifesciences Inc (GLSI)August 4, 2024 | investing.comGreenwich LifeSciences Provides Update on Expansion of Flamingo-01 into SpainAugust 1, 2024 | globenewswire.comGreenwich LifeSciences Set to Join Russell 2000 Index AgainJune 26, 2024 | globenewswire.comGreenwich LifeSciences Announces $2.5 Million Private PlacementJune 14, 2024 | globenewswire.comSee More Headlines GLSI Stock Analysis - Frequently Asked Questions How have GLSI shares performed this year? Greenwich LifeSciences' stock was trading at $10.52 on January 1st, 2024. Since then, GLSI shares have increased by 33.7% and is now trading at $14.06. View the best growth stocks for 2024 here. How were Greenwich LifeSciences' earnings last quarter? Greenwich LifeSciences, Inc. (NASDAQ:GLSI) posted its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.20). When did Greenwich LifeSciences IPO? Greenwich LifeSciences (GLSI) raised $7 million in an initial public offering (IPO) on Friday, September 25th 2020. The company issued 1,300,000 shares at a price of $5.75 per share. Aegis Capital served as the underwriter for the IPO. How do I buy shares of Greenwich LifeSciences? Shares of GLSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Greenwich LifeSciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Greenwich LifeSciences investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), Meta Platforms (META) and NVIDIA (NVDA). Company Calendar Last Earnings8/14/2024Today11/11/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:GLSI CUSIPN/A CIK1799788 Webwww.greenwichlifesciences.com Phone832-819-3232FaxN/AEmployees3Year FoundedN/APrice Target and Rating Average Stock Price Target$38.00 High Stock Price Target$38.00 Low Stock Price Target$38.00 Potential Upside/Downside+170.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,890,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-153.96% Return on Assets-141.52% Debt Debt-to-Equity RatioN/A Current Ratio5.34 Quick Ratio5.34 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.52 per share Price / Book27.04Miscellaneous Outstanding Shares13,150,000Free Float6,197,000Market Cap$184.89 million OptionableNot Optionable Beta1.62 The Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free Report This page (NASDAQ:GLSI) was last updated on 11/12/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored6-Figure Target for BTC by 2025According to Steven Lubka, head of a private equity firm with over $250M in assets under management, "Bitcoin ...Crypto 101 Media | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.Porter & Company | SponsoredBreaking News: Are Trump/Musk Planning an AI Takeover? (Shocking)Now that he is Donald Trump’s right-hand man… You owe it to yourself to see Elon Musk’s big AI prediction f...Traders Agency | SponsoredRe: Last Call for You to Get Wednesday’s TradeImagine a trading strategy that works when stocks rise, fall, or stay the same. Our strategy gives you three w...StockEarnings | SponsoredWith a $2B neighbor nearby, this underfollowed lithium explorer could have the next big strike!This Lithium Company Scoops Up the Largest Continuous Land Package in Brazil’s Lithium Boom Positioning the Co...Huge Alerts | SponsoredDiversification is for dummies.I went 20 years on Wall Street without a single losing year... My former hedge fund, Banyan Capital, was ra...Opportunistic Trader | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Greenwich LifeSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Greenwich LifeSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.